Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study

Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study

عرض إصدارات أخرى (1)
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Nash, P, Coates, L, Kivitz, A, Mease, P, Gladman, D, Covarrubias-Cobos, J, Fleishaker, D, Wang, C, Kudlacz, E, Menon, S, Fallon, L, Hendrikx, T, Kanik, K
التنسيق: Conference item
منشور في: BMJ Publishing Group Limited 2018

مواد مشابهة

مواد مشابهة